Jefferies recommendation update on BSX
Today, Jefferies raised its target price for Boston Scientific (BSX) stock from $42 to $45. The firm has a “buy” recommendation on the stock. Jefferies has shown increasing confidence in the upside potential of BSX on the back of its FDA approval for Eluvia, a drug-eluting stent system, on September 24. That day, BSX rose ~1.7% and was trading near a 14-year high. Jefferies analysts see an upside potential of 15% for the stock.
Today, BSX was up ~0.26% in afternoon trading.
Analysts’ consensus target price on BSX stock
Of the 24 analysts included in a recent Reuters survey, 21 (90%) have a “buy” or “strong buy” rating. The remaining three have “hold” ratings. As per these analysts, BSX stock has a consensus analysts’ target price of $39.64, which implies an upside potential of 3.1%.
On September 25, Wells Fargo also raised its target price on Boston Scientific from $42 to $43. The raise was also triggered by the approval of the Eluvia stent. On September 7, Needham, Stifel, and Canaccord Genuity also raised their target prices on the stock after the company announced its acquisition of Augmenix the previous day.
Be sure to check out all the data we’ve added to our quote pages. Now you can get a valuation snapshot, earnings and revenue estimates, historical data, and dividend information. Take a look!